GlassScriptPhysician profile
James S Bainbridge
NPI 1679566145
$5,139.78
in general payments reported to CMS, 2019-2025
27 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $74.81 · 2021: $765 · 2022: $682 · 2023: $1,503 · 2024: $729 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,694.91 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16, Embold Fibered |
| Saluda Medical Americas, INC. | $741.85 | 2023-2025 | Evoke, Evoke Scs |
| Spr Therapeutics, INC | $691.63 | 2019-2025 | Sprint Pns System |
| Painteq LLC | $473.27 | 2021-2023 | Painteq |
| Abbvie INC. | $413.75 | 2022-2025 | Botox, Qulipta |
| Relievant Medsystems, INC. | $163.90 | 2023 | Intracept |
| Abbott Laboratories | $139.90 | 2023 | Eterna |
| Nevro Corp. | $133.27 | 2020-2022 | |
| Nalu Medical, INC. | $126.83 | 2020-2022 | |
| Vertos Medical, INC. | $89.72 | 2022-2024 | Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.09 | 2024-2025 | Relistor |
| Medtronic, INC. | $68.10 | 2022-2024 | Intellis Adaptivestim |
| Bioventus LLC | $60.45 | 2023-2025 | Xcell, Stimrouter Implantable Kit, Durolane |
| Allergan, INC. | $39.68 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $35.44 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.13 | 2023 | Belbuca, Xtampza |
| Zimmer Biomet Holdings, INC. | $24.60 | 2023 | Gps III Platelet Concentration System |
| Spinal Simplicity, LLC | $21.99 | 2022 | |
| Lilly USA, LLC | $21.69 | 2019 | |
| Curonix LLC | $21.38 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $17.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.79 | 2023 | Quviviq |
| Biodelivery Sciences International, INC. | $12.08 | 2019 | |
| Amgen INC. | $11.83 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bainbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.